Teva Pharmaceutical Industries Limited Share Price London S.E.

Equities

0LER

US8816242098

Pharmaceuticals

Market Closed - London S.E. 09:00:00 03/05/2024 pm IST After market 11:50:28 pm
13.82 USD -1.25% Intraday chart for Teva Pharmaceutical Industries Limited 14.02 +1.45%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 15.86B 1,324B Sales 2025 * 16.4B 1,368B Capitalization 15.83B 1,322B
Net income 2024 * 1.54B 128B Net income 2025 * 1.44B 120B EV / Sales 2024 * 1.93 x
Net Debt 2024 * 14.82B 1,237B Net Debt 2025 * 12.25B 1,022B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
11.2 x
P/E ratio 2025 *
10.5 x
Employees 35,737
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.71%
More Fundamentals * Assessed data
Dynamic Chart
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis MT
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment DJ
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China CI
More news

Latest transcript on Teva Pharmaceutical Industries Limited

1 day+1.45%
1 week-0.74%
Current month-1.85%
1 month-3.02%
3 months+12.50%
6 months+52.09%
Current year+32.49%
More quotes
1 week
13.72
Extreme 13.72
14.18
1 month
12.49
Extreme 12.49
14.40
Current year
10.45
Extreme 10.45
14.41
1 year
7.10
Extreme 7.1
14.41
3 years
6.82
Extreme 6.82
14.41
5 years
6.14
Extreme 6.14
14.51
10 years
6.14
Extreme 6.14
25.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 01/23/01
Director of Finance/CFO 51 22/19/22
Chief Tech/Sci/R&D Officer - 01/22/01
Members of the board TitleAgeSince
Director/Board Member 77 01/15/01
Director/Board Member 59 09/20/09
Chairman 76 01/15/01
More insiders
Date Price Change Volume
03/24/03 14.05 -0.08% 7,592
02/24/02 14.06 +1.29% 608,816
01/24/01 13.88 -1.45% 12,887
30/24/30 14.08 -0.81% 13,718
29/24/29 14.2 +1.95% 11,135

Delayed Quote London S.E., May 03, 2024 at 09:00 pm IST

More quotes
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.98 USD
Average target price
15.74 USD
Spread / Average Target
+12.56%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW